Table 2.
Prevalence of Different HR-HPV Genotypes in Women with ASC-US (N=2393)
| Variate | Positive n (%) | Negative n (%) |
|---|---|---|
| Agea | ||
| 21–30 | 310 (51.2%) | 295 (48.8%) |
| 31–40 | 392 (46.9%) | 443 (53.1%) |
| 41–50 | 314 (46.8%) | 357 (53.2%) |
| 51–65 | 112 (43.9%) | 143 (56.1%) |
| >65 | 11 (40.7%) | 16 (59.3%) |
| HR-HPV | 1139 (47.6%) | 1254 (52.4%) |
| HPV16 | 226 (9.4%) | 2167 (90.6%) |
| HPV18 | 88 (3.7%) | 2305 (96.3%) |
| HPV31 | 64 (2.7%) | 2329 (97.3%) |
| HPV33 | 71 (3.0%) | 2322 (97.0%) |
| HPV35 | 26 (1.1%) | 2367 (98.9%) |
| HPV39 | 69 (2.9%) | 2324 (97.1%) |
| HPV45 | 33 (1.4%) | 2360 (98.6%) |
| HPV51 | 103 (4.3%) | 2290 (95.7%) |
| HPV52 | 329 (13.7%) | 2064 (86.3%) |
| HPV56 | 81 (3.4%) | 2312 (96.6%) |
| HPV58 | 201 (8.4%) | 2192 (91.6%) |
| HPV59 | 62 (2.6%) | 2331 (97.4%) |
| HPV66 | 60 (2.5%) | 2333 (97.5%) |
| HPV68 | 67 (2.8%) | 2326 (97.2%) |
Notes: aOnly consider the prevalence of HR-HPV.
Abbreviations: HR-HPV, high-risk human papillomavirus, including types HPV-16, −18, −31, −33, −35, −39, −45, −51, −52, −56, −58, −59, −66, −68. ASC-US, atypical squamous cells of undetermined significance.